Health Catalyst (NASDAQ:HCAT) Trading Up 8% on Analyst Upgrade

Health Catalyst, Inc. (NASDAQ:HCAT)’s stock price rose 8% during trading on Wednesday after Stephens raised their price target on the stock from $7.00 to $9.00. Stephens currently has an equal weight rating on the stock. Health Catalyst traded as high as $8.83 and last traded at $8.78. Approximately 84,323 shares were traded during trading, a decline of 85% from the average daily volume of 561,146 shares. The stock had previously closed at $8.13.

Other equities analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Piper Sandler dropped their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Evercore ISI upped their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Citigroup raised their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.71.

Insider Activity at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The trade was a 5.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HCAT. Quest Partners LLC purchased a new position in Health Catalyst during the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC raised its position in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP grew its position in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares during the last quarter. nVerses Capital LLC bought a new stake in Health Catalyst in the 3rd quarter valued at about $59,000. Finally, Perfromance Wealth Partners LLC acquired a new position in shares of Health Catalyst during the second quarter valued at $64,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Down 2.4 %

The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The company has a market cap of $514.17 million, a P/E ratio of -6.34 and a beta of 1.32. The stock has a 50 day moving average price of $8.13 and a 200 day moving average price of $7.20.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.22) earnings per share. Research analysts expect that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.